Odia, Y., Koschmann, C., ..., Daghistani, D., et al (2024). Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3K27M-mutant glioma.
Neuro-oncology,
Ahead of print(), .
View in Pubmed
Venneti, S., Kawakibi, A.R., ..., Daghistani, D., et al (2023). Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Neuro-oncology Advances,
13(11), 2370-2393.
View in Pubmed
Gardner, S.L., Tarapore, R.S., ..., Daghistani, D., et al (2022). Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Neuro-oncology Advances,
4(1), vdac143.
View in Pubmed